Poor Survival and Unique Challenges for Adolescents and Young Adults Diagnosed with Acute Lymphoblastic Leukemia

Strategic Insights -

Research published in the Journal of the National Cancer Institute (JNCI) Cancer Spectrum highlights the challenges faced by adolescents and young adults diagnosed with acute lymphoblastic leukemia (ALL). The study found that individuals in this age group experience poor survival rates and unique treatment challenges. The research aimed to evaluate facility-level factors and guideline-concordant care among adolescents and young adults with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices.

Key Takeaways:

  • Adolescents and young adults diagnosed with ALL between 15 and 39 years old face poor survival rates and unique challenges.
  • The study evaluated facility-level factors and guideline-concordant care among adolescents and young adults with ALL at NCORP practices.
  • Guideline-concordant care was observed in 68.8% of adolescents and young adults aged 22-39 years and nearly universal in those aged 15-21 years.
  • Adolescents and young adults receiving guideline-concordant care were younger than those who did not.
  • Adult/internal medicine clinical facilities had lower odds of guideline-concordant care, while facilities with communication between adult and pediatric counterparts, adolescent and young adult ALL clinical pathways, and/or adolescent and young adult-specific meetings had higher odds of guideline-concordant care.
  • Strategies to improve guideline-concordant care include facilitating communication and clinical pathways at adult/internal medicine clinical facilities treating adolescent and young adult ALL.

Statistics:

  • 196 adolescents and young adults received guideline-concordant care (median age = 19.5 years).
  • 31 adolescents and young adults did not receive guideline-concordant care (median age = 32.1 years).
  • 68.8% of adolescents and young adults aged 22-39 years and nearly universal in those aged 15-21 years received guideline-concordant care.
  • The odds ratio for guideline-concordant care at adult/internal medicine clinical facilities was 0.02 (95% confidence interval = 0.0 to 0.18).
  • The annual adolescent and young adult ALL volume was not statistically significantly associated with receiving guideline-concordant care.

Sources:

  • Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia. JNCI Cancer Spectrum, 2025;9(3).
  • University of Texas Health Science Center San Antonio.
  • Allison C. Grimes, Julie A. Wolfson, Michelle M. Nuno, Subhash Ramakrishnan, David S. Dickens, Michael E. Roth, Wendy Woods, Kandice S. Adams, Tawa Alabi, Melissa Beauchemin, Jennifer M. Levine, Michele Scialla, Koh B. Boayue, Charlotte L. Kerber, and Olivia.